Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 8
- Sponsors Novo Nordisk
- 23 Nov 2018 According to a Novo Nordisk media release, based on the PIONEER clinical trial programme (Consist of 10 studies), the company expects to share the results from this programme with regulatory authorities, in USA and EU, for review in the first half of 2019.
- 26 Oct 2018 Results presented in a Novo Nordisk media release.
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History